This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Investigators from multiple institutions conducted a retrospective study to compare the effectiveness of newer disease-modifying therapies (DMTs) to that of injectable DMTs in treating pediatric patients with multiple sclerosis (MS) or clinically isolated syndrome (CIS). Study participants were patients with onset of MS or CIS prior to the age of 18 years treated at 1 of 12 centers that are part of the US Network of Pediatric Multiple Sclerosis Centers and who were identified from network databases. Diagnoses were made using standardized criteria. Clinical data were collected on study participants using standardized case report forms. Patients were classified as receiving an injectable DMT (interferon-β, glatiramer acetate) or newer DMT, including dimethyl fumarate, fingolimod, teriflunomide, natalizumab, rituximab, ocrelizumab, and alemtuzumab. The primary outcome was relapse after starting DMT, …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.